Biotechnology - Biotechnology, Respiratory and Pulmonary

Filter

Popular Filters

1 to 25 of 69 results

US breakthrough status for InterMune’s pirfenidone

US breakthrough status for InterMune’s pirfenidone

21-07-2014

US biotech firm InterMune’s Esbriet (pirfenidone) has been granted Breakthrough Therapy designation…

BiotechnologyEsbrietFood and Drug AdministrationInterMunepirfenidoneRare diseasesRegulationRespiratory and PulmonaryUSA

AstraZeneca licensing deal validates Synairgen’s approach, say analysts

AstraZeneca licensing deal validates Synairgen’s approach, say analysts

14-07-2014

Anglo-Swedish drug major AstraZeneca’s recent $230 million deal with British respiratory drug development…

AsthmaAstraZenecaBiotechnologyInterferonLicensingRespiratory and PulmonaryRespiratory therapySNG001SynairgenUK

Actelion shares leap on positive Ph III data with selexipag

Actelion shares leap on positive Ph III data with selexipag

16-06-2014

Shares of Switzerland-based Actelion, Europe’s largest biotech firm, gained 15.1% to 104.70 Swiss francs…

ActelionBiotechnologyResearchRespiratory and Pulmonaryselexipag

AADi in-licenses Celgene’s ABI-009

20-05-2014

US clinical-stage biopharma company AADi says it has in-licensed ABI-009 from biotech firm Celgene. Financial…

AADiABI-009BiotechnologyCardio-vascularCelgeneOncologyRespiratory and Pulmonary

Boehringer’s nintedanib slows IPF disease progression in Ph III trial

19-05-2014

Results from the Phase III INPULSIS trials, published on-line yesterday in the New England Journal of…

BiotechnologyBoehringer IngelheimnintedanibResearchRespiratory and Pulmonary

Aslan Pharma signs agreement with CSL to develop novel therapy for asthma

19-05-2014

Singapore-based Aslan Pharmaceuticals has signed a global license agreement to develop an anti-interleukin…

ASLAN PharmaceuticalsBiotechnologyCSL LimitedCSL334LicensingRespiratory and Pulmonary

Ario Pharma strengthens scientific advisory board with two key appointments

Ario Pharma strengthens scientific advisory board with two key appointments

12-05-2014

UK-based biopharmaceutical company Ario Pharma has announced the appointment of Professor Peter Barnes…

BiotechnologyBoardroomPharmaceuticalRespiratory and PulmonaryUK

Cytos Biotech to wind down key operational activities

05-05-2014

Switzerland-based Cytos Biotechnology has entered into agreements with major creditors resulting in a…

BiotechnologyCYT003Cytos BiotechnologyFinancialLicensingRespiratory and Pulmonary

Negative results for asthma candidate cause Cytos Biotech to look at liquidation

14-04-2014

Swiss drug developer Cytos Biotechnology today revealed that the Phase IIb study of CYT003 in patients…

BiotechnologyFinancialResearchRespiratory and Pulmonary

Actelion says COMPASS-2 bosentan study fails primary endpoint

Actelion says COMPASS-2 bosentan study fails primary endpoint

17-03-2014

Europe’s largest biotech company Actelion has announced disappointing results of COMPASS-2, a Phase…

ActelionBiotechnologybosentanPfizerResearchRespiratory and PulmonarysildenafilTracleer

US Court upholds damages award in Actelion/Asahi litigation

14-03-2014

Switzerland-based Actelion says that the California Supreme Court has denied the firm’ petition for…

ActelionAsahi KaseiBiotechnologyfasudilFinancialLegalNorth AmericaRespiratory and PulmonaryUSA

Strong new data for InterMune’s Esbriet sees the firm’s stock rocket

26-02-2014

US biotech firm InterMune has released top-line data from ASCEND, a Phase III trial evaluating pirfenidone…

BiotechnologyEsbrietInterMuneResearchRespiratory and Pulmonary

Tracleer “whistleblower” case by the US Department of Justice dismissed

Tracleer “whistleblower” case by the US Department of Justice dismissed

10-01-2014

In connection with a qui tam proceeding ("whistleblower case"), Swiss biotech firm Actelion previously…

ActelionBiotechnologyLegalNorth AmericaRespiratory and PulmonaryTracleerUSA

Whooping cough vaccine agreement signed by ILiAD

09-01-2014

US biotech company ILiAD Biotechnologies has signed scientific collaboration and worldwide license agreements…

BiotechnologyFranceILiAD BiotechnologiesLicensingResearchRespiratory and PulmonaryUSA

Surprise US FDA approval for United Thera’s Orenitram ER for PAH

Surprise US FDA approval for United Thera’s Orenitram ER for PAH

23-12-2013

In what was seen by some observers as unexpected, the US Food and Drug Administration has approved United…

BiotechnologyNorth AmericaOrenitramRegulationRespiratory and PulmonaryTreprostinilUnited Therapeutics

Actelion’s PAH drug Opsumit approved in EU

Actelion’s PAH drug Opsumit approved in EU

22-12-2013

Switzerland-based Actelion has received European Commission approval for Opsumit (macitentan), a novel…

ActelionBiotechnologyEuropeOpsumitRegulationRespiratory and Pulmonary

Positive EMA/CHMP opinions for Actelion and Lundbeck

Positive EMA/CHMP opinions for Actelion and Lundbeck

27-10-2013

At its October month-end meeting, the European Medicines Agency’s Committee for Medicinal Products…

ActelionBiotechnologyBrintellixEuropeLundbeckNeurologicalOpsumitPharmaceuticalRegulationRespiratory and Pulmonary

Vectura and UCB to collaborate on severe inflammatory disease

Vectura and UCB to collaborate on severe inflammatory disease

30-09-2013

Vectura and UCB have entered into a collaboration for the development of an innovative biologic immuno-modulatory…

BiotechnologyEuropeInflammatory diseasesPharmaceuticalResearchRespiratory and PulmonaryUCBVectura

Further highlights from European Society of Cardiology meeting

03-09-2013

The ongoing European Society of Cardiology meeting in Amsterdam, Netherlands, continues to produce both…

ActelionalogliptinAmgenBiotechnologyCardio-vascularCytokineticsDiabetesomecamtiv mecarbilOpsumitPharmaceuticalResearchRespiratory and PulmonaryTakeda Pharmaceuticals

Actelion's Opsumit significantly reduced risk of morbidity/mortality events

29-08-2013

Results of SERAPHIN, the pivotal study with Switzerland-based Actelion's (SIX: ATLN) macitentan (trade…

ActelionBiotechnologymacitentanOpsumitResearchRespiratory and Pulmonary

Shares jump as Array BioPharma reports positive results for asthma drug

23-07-2013

US biotech firm Array BioPharma (Nasdaq: ARRY) saw its shares jump as it announced that its drug candidate…

Array BioPharmaBiotechnologyNorth AmericaResearchRespiratory and Pulmonary

INTERVIEW: Verona Pharma's CEO Jan-Anders Karlsson on the company's hope for two

INTERVIEW: Verona Pharma's CEO Jan-Anders Karlsson on the company's hope for two "first-in-class" compounds for respiratory diseases

22-07-2013

With a clear passion for helping patients and a self-confessed need to know everything that is happening…

BiotechnologyBoardroomEuropePharmaceuticalRespiratory and PulmonaryVerona Pharma

GlaxoSmithKline and Theravance withdraw Japan NDA for Relvar Ellipta in COPD

12-07-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) revealed on Friday…

Asia-PacificBiotechnologyGlaxoSmithKlinePharmaceuticalRegulationRelvar ElliptaRespiratory and PulmonaryTheravance

Ireland's HSE to reimburse InterMune's Esbriet for IPF

08-07-2013

US biotech firm InterMune's (Nasdaq: ITMN) UK subsidiary says that Ireland's Health Service Executive…

BiotechnologyEsbrietEuropeInterMunePricingRegulationRespiratory and Pulmonary

1 to 25 of 69 results

Back to top